A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH (NCT06920043)
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site β Chandler, Arizona
Age range: 18 Years to 75 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- GSK Investigational Site β Chandler, Arizona
- GSK Investigational Site β Mesa, Arizona
- GSK Investigational Site β Tucson, Arizona
- GSK Investigational Site β Fresno, California
- GSK Investigational Site β Lancaster, California
- GSK Investigational Site β Pasadena, California
- GSK Investigational Site β Rialto, California
- GSK Investigational Site β Santa Maria, California
- GSK Investigational Site β Miami, Florida
- GSK Investigational Site β Viera, Florida
- GSK Investigational Site β Marietta, Georgia
- GSK Investigational Site β Baltimore, Maryland
- GSK Investigational Site β Kansas City, Missouri
- GSK Investigational Site β New York, New York
- GSK Investigational Site β Fayetteville, North Carolina
- GSK Investigational Site β Wilson, North Carolina
- GSK Investigational Site β Austin, Texas
- GSK Investigational Site β Austin, Texas
- GSK Investigational Site β Austin, Texas
- GSK Investigational Site β Dallas, Texas
- GSK Investigational Site β Georgetown, Texas
- GSK Investigational Site β Houston, Texas
- GSK Investigational Site β Houston, Texas
- GSK Investigational Site β Houston, Texas
- GSK Investigational Site β Pasadena, Texas
π Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metabolic Dysfunction-Associated Steatohepatitis
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) β Miami, Florida
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRΞ²) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) β Chandler, Arizona
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) β Miami, Florida
Explore by condition: All Metabolic Dysfunction-Associated Steatohepatitis clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.